77 results on '"Ahn, Sylvie A."'
Search Results
2. Survival analysis of a large Belgian heart failure cohort with reduced ejection fraction
3. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
4. Established and novel gender dimorphisms in type 2 diabetes mellitus: Insights from a multiethnic cohort
5. Additional Prognostic Value of 2D Right Ventricular Speckle-Tracking Strain for Prediction of Survival in Heart Failure and Reduced Ejection Fraction
6. Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetes
7. High rates of atherogenic dyslipidemia, β-cell function loss, and microangiopathy among Turkish migrants with T2DM
8. Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients
9. PROGNOSTIC VALUE OF RIGHT VENTRICULAR SYSTOLIC DYSFUNCTION IN HEART FAILURE WITH REDUCED EJECTION FRACTION
10. Head to head comparison of intact and C-terminal fibroblast growth factor 23 in heart failure patients with reduced ejection fraction
11. Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia
12. Size, density and cholesterol load of HDL predict microangiopathy, coronary artery disease and β-cell function in men with T2DM
13. Le rapport [HDL-C/apoA-I] : un marqueur polyvalent du risque cardiométabolique et des complications vasculaires chez la femme diabétique de type 2
14. Un taux bas de lipoprotéine (a) est associé à une insulinorésistance, une perte accrue de fonction β, et à la latéralisation droitière chez les patients DT2
15. Right Ventricular Systolic Dysfunction Assessed by Cardiac Magnetic Resonance Is a Strong Predictor of Cardiovascular Death After Coronary Bypass Grafting
16. Soluble ST2, the vitamin D/PTH axis and the heart: New interactions in the air?
17. The normal-weight type 2 diabetes phenotype revisited
18. LONG-TERM EFFECT OF EARLY ENALAPRIL THERAPY ON CAUSES OF DEATH IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION: A 27-YEAR FOLLOW-UP OF SOLVD IN BELGIUM
19. Predictive Value of 1, 25-dihydroxyvitamin D to PTH(1-84) Ratios for Cardiovascular Death in Heart Failure
20. Prognostic Impact of Hypertrabeculation and Noncompaction Phenotype in Dilated Cardiomyopathy
21. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients
22. SOLUBLE RECEPTOR FMS LIKE TYROSINE KINASE 1 TESTING IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION
23. Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure
24. Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction
25. Serum Galectin-3 Is Elevated and Related to Cardiac Biomarkers in Types 2 Diabetes
26. Aldosterone and Parathyroid Hormone in Heart Failure: Interaction and Prognosis Impact
27. Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes
28. VALIDITY OF A NOVEL AUTOMATED ASSAY FOR GALECTIN-3 TESTING IN PATIENTS WITH REDUCED EJECTION FRACTION
29. Parental brevity linked to cardiometabolic risk in diabetic descendants
30. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction
31. Novel sexual dimorphisms of sleep apnea syndrome in diabetes
32. Value of proBNP1–108 testing for the risk stratification of patients with systolic heart failure
33. USEFULNESS OF PLASMA GALECTIN-3 IN CONGESTIVE HEART FAILURE: RELATIONSHIPS WITH ECHOCARDIOGRAPHIC PARAMETERS AND SURVIVAL
34. C-terminal FGF23 is a strong predictor of survival in systolic heart failure
35. Prognostic Utility of the Seattle Heart Failure Model To Predict Survival in Patients With Heart Failure
36. FGF23: A New Trigger for Secondary Hyperparathyroidism in Heart Failure?
37. Chromogranin A Predicts 6 Years Mortality in Patients With Reduced Ejection Fractions
38. The multi-faceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes
39. FGF23 IS A STRONG PREDICTOR OF SURVIVAL IN CONGESTIVE HEART FAILURE
40. Prognostic Value of Myocardial Viability by Delayed-Enhanced Magnetic Resonance in Patients With Coronary Artery Disease and Low Ejection Fraction
41. Measurement of NT-proBNP with LOCI® technology in heart failure patients
42. Galectin-3 as a New Remodeling Marker in Heart Failure: Comparison to Other Neurohumoral Biomarkers
43. Heterogeneity of ProBNP1-108 to BNP and ProBNP1-108 to Nt-proBNP Ratios in Congestive Heart Failure
44. Early Enalapril Therapy on Long-Term Mortality in Patients with Asymptomatic Left Ventricular Systolic Dysfunction: A 22-Year Follow-Up of SOLVD in Belgium
45. SELECTIVE PROFILING OF CARDIAC NEUROHORMONES PREDICTS MODES OF DEATH IN CONGESTIVE HEART FAILURE
46. The elusive type 2 diabetes individual achieving tight blood pressure target: A phenotypic study
47. Increased Plasma Chromogranin A Is Related to Congestive Heart Failure
48. Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes
49. HIGH FERRITIN LEVELS CONFER LOWER CARDIOVASCULAR RISK IN TYPE 2 DIABETES
50. GAIN IN LIFE EXPECTANCY IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION TREATED EARLY WITH ENALAPRIL: A 23-YEAR FOLLOW-UP OF SOLVD COHORT IN BELGIUM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.